Adherence patterns in naïve and prevalent use of infliximab and its biosimilar

INTRODUCTION: Although short-term clinical trials have demonstrated that switching from infliximab (INF) bio-originator to its biosimilar is safe with no significant loss of efficacy, there are limited real-world data comparing their patterns of use and adherence. METHODS: Using 2015–2018 IBM Market...

Descripción completa

Detalles Bibliográficos
Autores principales: Alanaeme, Chibuike J., Sarvesh, Sujith, Li, Cynthia Y., Bernatsky, Sasha, Curtis, Jeffrey R., Yun, Huifeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9623955/
https://www.ncbi.nlm.nih.gov/pubmed/36316762
http://dx.doi.org/10.1186/s41927-022-00295-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9623955/
https://www.ncbi.nlm.nih.gov/pubmed/36316762
http://dx.doi.org/10.1186/s41927-022-00295-7

Ejemplares similares